Spots Global Cancer Trial Database for metastatic disease
Every month we try and update this database with for metastatic disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Negative Pressure Wound Therapy vs. Sterile Dressing for Patients Undergoing Thoracolumbar Spine Surgery | NCT03632005 | Metastatic Dise... Spinal Cord Inj... Spinal Degenera... Spinal Deformit... | Vacuum Assisted... Sterile dressin... | 17 Years - | University of British Columbia | |
| Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer | NCT02793219 | Prostate Cancer | Sipuleucel-T Docetaxel | 18 Years - | The University of Texas Health Science Center, Houston | |
| Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study | NCT04014530 | Colorectal Canc... Endometrium Can... | Ataluren + Pemb... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Communication Strategies to Introduce Psychology Services | NCT03035448 | Malignant Neopl... | Questionnaires Video Presentat... | 18 Years - | M.D. Anderson Cancer Center | |
| Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study | NCT04014530 | Colorectal Canc... Endometrium Can... | Ataluren + Pemb... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer | NCT01679405 | Metastatic Dise... | BIBW 2992 | 18 Years - | Johannes Gutenberg University Mainz | |
| Stereotactic Radiation Therapy for Pediatric Sarcomas | NCT01763970 | Sarcoma Metastatic Dise... Bony Sites | SBRT | 4 Years - 40 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment | NCT05167500 | Metastatic Non ... | Lorlatinib | 18 Years - | Fundación GECP | |
| BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer | NCT01679405 | Metastatic Dise... | BIBW 2992 | 18 Years - | Johannes Gutenberg University Mainz | |
| Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer | NCT00365599 | Breast Cancer | suberoylanilide... tamoxifen citra... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy | NCT01450683 | Prostate Cancer Prostatic Neopl... Castrate-resist... Androgen-insens... Hormone-refract... Metastatic Dise... | Itraconazole | 18 Years - | Stanford University | |
| Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine | NCT01020006 | Pancreatic Canc... Ductal Adrenoca... Exocrine Pancre... | PCI-27483 Gemcitabine | 18 Years - | Pharmacyclics LLC. | |
| Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer | NCT00593060 | Colorectal Canc... Colorectal Aden... | Temsirolimus Cetuximab | 18 Years - | Massachusetts General Hospital | |
| N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy | NCT02142036 | Metastatic Canc... | EMA-approved AT... | 18 Years - | Oslo University Hospital | |
| Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer | NCT00805688 | Pancreatic Canc... | Questionnaires Blood Draws Pedometer | 18 Years - | M.D. Anderson Cancer Center | |
| Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies | NCT01924689 | Solid Tumor Mal... | Clostridium nov... | 18 Years - | BioMed Valley Discoveries, Inc | |
| Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) | NCT00609401 | Metastatic Dise... Renal Cell Carc... | Nexavar (Sorafe... IL-2 | 18 Years - | Italian Trial in Medical Oncology | |
| BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer | NCT01263782 | Lung Cancer | Carboplatin Pemetrexed Bevacizumab Cixutumumab | 18 Years - | M.D. Anderson Cancer Center | |
| Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses | NCT05674825 | Cancer | Targeted agent Standard of car... | 18 Years - | Medical College of Wisconsin | |
| QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel | NCT02559674 | Advanced Pancre... | Gemcitabine Nab-paclitaxel ALT-803 | 18 Years - | Altor BioScience | |
| Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal | NCT00480389 | Renal Cell Carc... Metastatic Dise... | Sorafenib | 18 Years - | University Health Network, Toronto | |
| Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma | NCT00406900 | Melanoma Radiotherapy Metastatic Dise... | Treatment of me... | - | Ludwig-Maximilians - University of Munich | |
| A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies | NCT01542047 | Cancer, Metasta... | Carboplatin Pazopanib | 18 Years - | New Mexico Cancer Care Alliance | |
| Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer | NCT00557206 | Neoplasms Head and Neck N... | Oxaliplatin and... | 18 Years - | Minneapolis Veterans Affairs Medical Center | |
| Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma | NCT03728842 | Melanoma; Renal... | Blood collectio... Data collection... | 18 Years - | Indiana University | |
| BiPAP-Vapotherm RCT | NCT01518140 | Advanced Cancer... | Oxygen Delivery... Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer | NCT01020305 | Prostate Cancer Prostatic Neopl... Castrate-resist... Androgen-insens... Hormone-refract... Metastatic Dise... | Temsirolimus Casodex (bicalu... | 18 Years - | Stanford University | |
| Minocycline Study in Pancreatic Cancer Patients | NCT01693523 | Pancreatic Canc... | Minocycline Placebo Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study | NCT03705403 | NSCLC Stage IV Metastatic Dise... | Darleukin Radiation | 18 Years - | Maastricht University Medical Center | |
| Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients | NCT03823989 | Cancer Solid Tumor Metastatic Dise... | Promitil EBR | 18 Years - | Lipomedix Pharmaceuticals Inc. | |
| A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo | NCT02496832 | Pancreatic Aden... Advanced Diseas... Metastatic Dise... | 18F-Fluoroazomy... | 18 Years - | University Health Network, Toronto | |
| N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy | NCT02142036 | Metastatic Canc... | EMA-approved AT... | 18 Years - | Oslo University Hospital | |
| Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial | NCT04307329 | Breast Cancer | Monalizumab Trastuzumab | 18 Years - | The Netherlands Cancer Institute | |
| Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial | NCT04307329 | Breast Cancer | Monalizumab Trastuzumab | 18 Years - | The Netherlands Cancer Institute | |
| Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC) | NCT02054793 | Prostate Cancer Castration-resi... | Itraconazole Orteronel | 18 Years - | Johns Hopkins University | |
| Stereotactic Radiation Therapy for Pediatric Sarcomas | NCT01763970 | Sarcoma Metastatic Dise... Bony Sites | SBRT | 4 Years - 40 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer | NCT00212615 | C04.588.274.476... | Oxaliplatin (El... Capecitabine (X... | 18 Years - | Odense University Hospital | |
| Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer | NCT02793219 | Prostate Cancer | Sipuleucel-T Docetaxel | 18 Years - | The University of Texas Health Science Center, Houston | |
| Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies | NCT01924689 | Solid Tumor Mal... | Clostridium nov... | 18 Years - | BioMed Valley Discoveries, Inc | |
| Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal | NCT00480389 | Renal Cell Carc... Metastatic Dise... | Sorafenib | 18 Years - | University Health Network, Toronto | |
| Single Agent Regorafenib in Refractory Advanced Biliary Cancers | NCT02115542 | Cancer of the B... | Regorafenib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial | NCT05188911 | Prostate Cancer Castration-resi... Metastatic Dise... | Abiraterone Prednisone Androgen depriv... | 18 Years - 85 Years | Fudan University | |
| A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC) | NCT02819882 | Breast Neoplasm... | No intervention | 18 Years - | Spanish Breast Cancer Research Group | |
| PF-03446962 in Relapsed or Refractory Urothelial Cancer | NCT01620970 | Transitional Ce... | PF03446962 | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients | NCT03823989 | Cancer Solid Tumor Metastatic Dise... | Promitil EBR | 18 Years - | Lipomedix Pharmaceuticals Inc. | |
| PF-03446962 in Relapsed or Refractory Urothelial Cancer | NCT01620970 | Transitional Ce... | PF03446962 | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy | NCT01450683 | Prostate Cancer Prostatic Neopl... Castrate-resist... Androgen-insens... Hormone-refract... Metastatic Dise... | Itraconazole | 18 Years - | Stanford University | |
| Negative Pressure Wound Therapy vs. Sterile Dressing for Patients Undergoing Thoracolumbar Spine Surgery | NCT03632005 | Metastatic Dise... Spinal Cord Inj... Spinal Degenera... Spinal Deformit... | Vacuum Assisted... Sterile dressin... | 17 Years - | University of British Columbia | |
| CPCT-02 Biopsy Protocol | NCT01855477 | Solid Tumors Metastatic Dise... | Histological bi... | 18 Years - | Foundation CPCT | |
| IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study | NCT03705403 | NSCLC Stage IV Metastatic Dise... | Darleukin Radiation | 18 Years - | Maastricht University Medical Center | |
| Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer | NCT00557206 | Neoplasms Head and Neck N... | Oxaliplatin and... | 18 Years - | Minneapolis Veterans Affairs Medical Center | |
| The Role of Surgery for Esophageal Cancer With Metastatic Disease (M1) | NCT06424210 | Esophageal Canc... Metastatic Dise... | 20 Years - | National Taiwan University Hospital | ||
| PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients With LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells) | NCT04854213 | Colorectal Canc... | Stereotactic Bo... | 18 Years - 80 Years | National Cancer Institute, Naples | |
| BiPAP-Vapotherm RCT | NCT01518140 | Advanced Cancer... | Oxygen Delivery... Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial | NCT04307329 | Breast Cancer | Monalizumab Trastuzumab | 18 Years - | The Netherlands Cancer Institute | |
| Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer | NCT06192680 | Colorectal Canc... | Liposomal irino... Capecitabine Bevacizumab | 18 Years - 80 Years | Harbin Medical University | |
| Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy | NCT00278993 | Prostate Cancer | E7389 | 18 Years - | Eisai Inc. | |
| Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma | NCT02631590 | Biliary Carcino... Gall Bladder Ca... Cholangiocarcin... Gastrointestina... | Cisplatin Gemcitabine Copanlisib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer | NCT02795819 | Renal Cell Carc... Soft Tissue Sar... Metastatic Dise... | AR-42 Pazopanib | 18 Years - | Virginia Commonwealth University | |
| Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic | NCT01703910 | Adenocarcinoma ... Adenocarcinoma ... Metastatic Dise... | Arm A chemother... arm B chemother... | 18 Years - 76 Years | Centro Nacional de Investigaciones Oncologicas CARLOS III | |
| MAnagement of METastatic Disease In Campania (MAMETIC) | NCT04595032 | Metastatic Dise... | 3DCRT, IMRT, VM... | 18 Years - | National Cancer Institute, Naples | |
| Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy | NCT00278993 | Prostate Cancer | E7389 | 18 Years - | Eisai Inc. | |
| Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study | NCT04014530 | Colorectal Canc... Endometrium Can... | Ataluren + Pemb... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses | NCT05674825 | Cancer | Targeted agent Standard of car... | 18 Years - | Medical College of Wisconsin | |
| Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors | NCT00395434 | Tumors | Combretastatin ... Bevacizumab (Av... | 18 Years - | Mateon Therapeutics | |
| Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) | NCT00609401 | Metastatic Dise... Renal Cell Carc... | Nexavar (Sorafe... IL-2 | 18 Years - | Italian Trial in Medical Oncology | |
| Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN) | NCT02856867 | Esophagogastric... Metastatic Dise... No Previous Che... | Nintedanib Fluorouracil Leucovorin Oxaliplatin Placebo | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy | NCT01484860 | Adenocarcinoma ... Metastatic Dise... | AUY922 | 18 Years - | University Health Network, Toronto | |
| REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer | NCT04077099 | NSCLC | REGN5093 | 18 Years - | Regeneron Pharmaceuticals | |
| Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies | NCT01118819 | Solid Tumor Mal... | Clostridium nov... | 18 Years - | BioMed Valley Discoveries, Inc | |
| Safety and Targeting of Anti-hk2 Antibody in mCRPC | NCT04116164 | Castration-Resi... Metastatic Dise... | 111In-DOTA-h11B... | 18 Years - | SpectronRX | |
| Open-Label,Non-Randomized Trial of Cisplatin Chemotherapy in BRCA1-Positive Metastatic Breast Cancer Patients | NCT01611727 | BRCA1 Mutation Metastatic Brea... | Cisplatin | 18 Years - | Pomeranian Medical University Szczecin | |
| Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) | NCT00609401 | Metastatic Dise... Renal Cell Carc... | Nexavar (Sorafe... IL-2 | 18 Years - | Italian Trial in Medical Oncology | |
| Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer | NCT01875380 | Colorectal Neop... Metastatic Dise... | Regorafenib | 18 Years - | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | |
| Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma | NCT02066285 | Solitary Fibrou... Extraskeletal M... | Pazopanib | 18 Years - | Grupo Espanol de Investigacion en Sarcomas | |
| Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma | NCT03728842 | Melanoma; Renal... | Blood collectio... Data collection... | 18 Years - | Indiana University | |
| Docetaxel Followed by Provenge in Metastatic Prostate Cancer | NCT02793765 | Prostate Cancer | Docetaxel Sipuleucel-T | 18 Years - | The University of Texas Health Science Center, Houston | |
| Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer | NCT00579683 | Unresectable or... | Tumor core biop... | - | Memorial Sloan Kettering Cancer Center | |
| Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine | NCT01020006 | Pancreatic Canc... Ductal Adrenoca... Exocrine Pancre... | PCI-27483 Gemcitabine | 18 Years - | Pharmacyclics LLC. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
